 Eight patients with pulmonary hypertension New York Heart Association functional class III or IV associated with COPD were included in a pilot study between 2004 and 2005. Inclusion criteria were: COPD was defined by FEV1FVC 70 of reference values; resting mean pulmonary artery pressure assessment by right pulmonary catheterization 25mmHg with mean pulmonary capillary wedge pressure 15mmHg, PaO2 60mmHg at rest or PaO2 60mmHg associated with significant fall in O2 saturation with exercise; oxygen treatment initiated more than six months previously. Exclusion criteria were: clinical or respiratory instability during the three months before the inclusion in the study; corticosteroids therapy 0.5mgkgday of prednisolone or as equivalent; hepatic prothrombin time 50 or renal creatininemia 130μmolL failure; diabetes; left ventricular dysfunction; PSA prostatic antigens 2,5ngml and past history or diagnosis of cancer. The study was conducted in accordance with the Good Clinical Practices Guidelines. The study protocol was approved by the ethics review board of the University Hospital of Bordeaux France. Written informed consent was obtained for all patients and investigations were conducted according to the institutional guidelines and to the Helsinki principles. This trial conducted enrollment between 2004 and 2005, but had not been registered in ClinicalTrials.gov because it preceded this policy.Study design: The dose of oral DHEA administered was 200 mg once daily for three months. At baseline and after three months of treatment, clinical evaluation included 6MWT, Borg dyspnea index, systolic and diastolic blood pressure, right heart catheterisation, lung function testing and serum DHEA levels were performed. 